Glossary of peptide terminology (revision 15)
Old revision·02:26, 30 May 2025·CommaCarys
This is an old revision of this page, as it stood at 02:26, 30 May 2025, saved by CommaCarys with the summary expand the comparison so all four subjects have the same rows. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Glossary of peptide terminologyReference material | |
|---|---|
| Scope | Terms used across this wiki |
| Arrangement | By domain, then alphabetically |
| List infobox · conventions | |
This glossary defines terms used across PeptidePedia Wiki. Each entry gives a short definition and, where a full article exists, links to it. Terms are grouped by domain and ordered alphabetically within each group.[1]
Definitions here are deliberately brief. Where a term carries a distinction that matters — purity against content, sterility against endotoxin freedom, contraindication against warning — the entry states the distinction and the article develops it.[2]
The glossary is not a substitute for the articles and does not attempt completeness.[3]
Chemistry and manufacture
[edit]- Aib
- α-aminoisobutyric acid, a non-proteinogenic residue used to block DPP-4 cleavage.
- Acylation
- Attachment of a fatty acid to a peptide, usually for albumin binding.
- Crude
- The material obtained directly after cleavage, before purification. See Crude peptide.
- Deletion sequence
- A synthesis by-product missing one or more residues.
- Fmoc
- The base-labile temporary protecting group scheme dominating peptide synthesis.
- Linker
- The resin attachment defining the C-terminal functionality of the finished peptide.
- Lyophilisation
- Freeze-drying; the isolation step producing the powder in a vial. See Lyophilisation.
- SPPS
- Assembly of a peptide on an insoluble support.
- TFA salt
- The salt form in which most reverse-phase-purified peptides are isolated.[1]
Analysis and documentation
[edit]- Area percent
- Main-peak area over total integrated area; normalised, and independent of quantity.
- Batch number
- The identifier linking a container to production records.
- COA
- The document a supplier issues reporting determinations on a lot.
- Endotoxin
- Lipopolysaccharide from Gram-negative bacteria; survives sterilisation.
- Karl Fischer
- A water-specific determination, as distinct from loss on drying.
- LOD
- The lowest level at which presence can be distinguished from background.
- Peptide content
- The mass fraction of a solid that is peptide; not purity.
- Reference standard
- A characterised material of assigned content used for calibration.
- Retention time
- Time from injection to peak; characteristic under fixed conditions.
- Stability-indicating
- Of a method, able to resolve degradation products from the parent.[2]
Clinical and evidence
[edit]- Placebo-adjusted
- The difference between treatment and comparator arms.
- ITT
- Analysis by randomised assignment, regardless of treatment received.
- NNT
- Reciprocal of the absolute risk reduction, over a stated period.
- Surrogate endpoint
- A measure standing in for an outcome of direct importance.
- Estimand
- A precise statement of the quantity a trial estimates, including how discontinuation is handled.
- Contraindication
- A circumstance in which labelling directs a product is not used; distinct from a warning.
- Research use only
- A presentation, not a quality grade; such material is not approved for human use.[4]
Additional terms are defined where they first appear in the articles. Suggestions for entries belong on the talk page.[3]
See also
References
- ^ a b United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
- ^ a b United States Pharmacopeia, General Chapter <621>, Chromatography.
- ^ a b PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see Project:Sourcing guidelines).
- ^ Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.